Current Editions
FDA’s Marks outlines plans to energize gene therapy, hopes for gene editing
CBER Director Peter Marks believes regulatory policies can help overcome barriers that are slowing gene therapy
Regulation
Emerging Company Profile
Visgenx: Taking retinal gene therapy beyond rare disease
First program delivers an enzyme involved in the fatty acid synthesis pathway for patients with dry AMD
Data Byte
Keytruda still growing
Opdivo started stronger, but has long since plateaued. Their sales differential
FDA label expansions: March brought full approvals of Elahere, Rybrevant
Plus: Approvals in earlier cancer lines for Rybrevant and Opdivo, and new indications for four more products
Discovery & Translation
Science spotlight: Tumor T cell restriction mechanism, plus programmable RNA excision
BioCentury’s roundup of translational innovations
Finance
Public equity report: Cidara resets with $240M PIPE
Plus: Centessa raises $100M in first follow-on since 2021 IPO
BioCentury ISSN 1097-7201